(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-(2H3)methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one

• ChemBase ID: 160606
• Molecular Formular: C30H25F10NO3
• Molecular Mass: 637.508432
• Monoisotopic Mass: 637.16747587
• SMILES: O1[C@@H]([C@@H](N(C1=O)Cc1c(ccc(c1)C(F)(F)F)c1cc(c(cc1OC)F)C(C)C)C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F
• Canonical SMILES: COc1cc(F)c(cc1c1ccc(cc1CN1C(=O)O[C@@H]([C@@H]1C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C
• InChI: InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
• InChIKey: MZZLGJHLQGUVPN-HAWMADMCSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-(^2H₃)methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one
• IUPAC Traditional name: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-5-isopropyl-2-(^2H₃)methoxyphenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one
• Synonyms: (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-(methoxy-d3)-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone; (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-(methoxy-d3)-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one; MK 0859-d3; Anacetrapib-d3

Database IDs

• CAS Number: 1061715-90-9
• PubChem SID: 162254741
• PubChem CID: 59818335

CALCULATED PROPERTIES

• H Acceptors: 2
• H Donor: 0
• LogD (pH = 5.5): 9.300929
• LogD (pH = 7.4): 9.300929
• Log P: 9.300929
• Molar Refractivity: 141.1558 cm^3
• Polarizability: 52.43183 Å^3
• Polar Surface Area: 38.77 Å^2
• Rotatable Bonds: 9
• Lipinski's Rule of Five: false

DETAILS

Toronto Research Chemicals - A637202

A labelled orally active and potent cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis, in particular dyslipidemia.

REFERENCES

• Krishna, R. et al.: Br. J. Clin. Pharmacol., 67, 520 (2009)
• Vergeer, M. et al.: Nat. Clin. Pract. Cardiovasc. Med., 5, 302 (2009)
• Masson, D.: Curr. Opin. Invest. Drugs, 10, 980 (2009)